

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

INSIDE INFORMATION: SUSPENSION OF TRADING OF A SHARES REGARDING THE PLAN FOR SIGNIFICANT TRANSACTION

This announcement is made by the board of directors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) pursuant to the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Company announces that it is contemplating a significant transaction which may involve major asset restructuring. Given the uncertainty in the significant transaction and in order to ensure fair disclosure of information, safeguard the interests of investors and prevent unusual fluctuation in the price of the A shares of the Company, the trading in the Company’s A shares on the Shanghai Stock Exchange will be suspended commencing from 31 October 2017 in accordance with the applicable laws and regulations of the PRC.

The Company will disclose whether to proceed with the aforesaid significant transaction(s) as soon as practicable and will announce the progress in respect thereof every 5 trading days commencing from the date on which trading of the Company’s A shares is suspended.

There is no assurance that the significant transaction will either materialise or eventually be consummated. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 30 October 2017

As at the date of this announcement, the board of directors of the Company comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.